首页> 外文OA文献 >Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy

【2h】

Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy

机译：三官能双特异性抗体的潜力依赖于树突状细胞：肿瘤免疫疗法新方法的理由

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Nina Eissler; Josef Mysliwietz; Nina Deppisch; Peter Ruf; Horst Lindhofer; Ralph Mocikat;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy [J] . Nina Eissler, Josef Mysliwietz, Nina Deppisch, Molecular medicine. . 2013,第1期

机译：三功能双特异性抗体Surek的潜力取决于树突状细胞：肿瘤免疫治疗新方法的原理。
2. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [J] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, Journal of Translational Medicine . 2013,第1期

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
3. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism. [J] . Boehrer S, Schroeder P, Mueller T, Anti-cancer drugs . 2011,第6期

机译：三功能双特异性抗体FBTA05在慢性淋巴细胞白血病的离体细胞中的细胞毒作用取决于免疫介导的机制。
4. Improved T Cell Activation Bioassays to Advance the Development of Bispecific Antibodies and Engineered T Cell Immunotherapies [C] . Gopal Krishnan, Pete Stecha, Denise Garvin, Protein Engineering Summit. . 2018

机译：改进的T细胞活化生物测定促进双特异性抗体和工程化T细胞免疫检查的发育
5. Development of a novel antibody molecule for redirected T cell immunity to tumor cells: The bispecific single chain antibody [D] . Gruber, Meegan Minori 1996

机译：用于重定向T细胞对肿瘤细胞免疫的新型抗体分子的开发：双特异性单链抗体
6. Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy [O] . Nina Eissler, Josef Mysliwietz, Nina Deppisch, 2013

机译：三功能双特异性抗体Surek的潜力取决于树突状细胞：肿瘤免疫疗法的新方法的理由。
7. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [O] . 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
8. Breast Cancer Immunotherapy With Intra-Tumoral Injection of Genetically Modified Dendritic Cells [R] . Kim, S. 2003

机译：肿瘤内注射转基因树突状细胞的乳腺癌免疫治疗

Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅